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Abstract
Background: The risk of bleedings in transcatheter aortic valve implantation (TAVI) patients
increases due to age and concomitant diseases. The aim of the study was to assess the risk of
bleedings, their influence on early prognosis of TAVI patients and utility of the TIMI and
GUSTO scales in the evaluation of bleeding and in prediction of blood transfusion.
Methods: This was a single center study of in-hospital bleedings in 56 consecutive TAVI
patients. Bleedings were classified according to the GUSTO and TIMI scales. HASBLED‘s
scale risk factors, diabetes mellitus, female sex, the route of bioprosthesis implantation and in-
hospital antithrombotic treatment were analyzed. Statistical analysis consisted of c2, Fisher’s
exact, Wilcoxon tests and logistic regression analysis.
Results: Serious bleedings occurred in 35 (62.5%) patients. There was no significant
correlation with HASBLED score. History of anemia was a significant predictor of bleeding in
GUSTO (p = 0.0013) and TIMI (p = 0.048) scales. No bleedings in patients receiving
vitamin K antagonists (VKA) pre- and VKA plus clopidogrel post intervention were observed.
Patients with bleedings according to the GUSTO scale more often required blood tranfusion
than in TIMI scale (p = 0.03).
Conclusions: History of anemia is the strongest predictor of serious bleedings. VKA before
and VKA with clopidogrel after TAVI are safer than dual antiplatelet or triple therapy. The
TIMI and GUSTO scales can adequately classify bleeding after TAVI, however the GUSTO
better predicts transfusions. (Cardiol J 2013; 20, 2: 125–133)
Key words: transcatheter aortic valve implantation (TAVI), bleeding complications,
aortic stenosis, antithrombotic therapy
126
Cardiology Journal 2013, Vol. 20, No. 2
www.cardiologyjournal.org
Introduction
The rules of antithrombotic treatment after sur-
gical aortic valve replacement are known [1]. It is ac-
cepted that patients after thranscatheter aortic valve
implantation (TAVI) receive dual antiplatelet thera-
py (DAPT) with acetylsalicylic acid and clopidogrel
in prevention of thrombo-embolic complications [2].
Until now there have not been any prospective stud-
ies assessing the efficacy and safety of this type of
treatment. The risk of bleeding complications in po-
pulation of patients undergoing TAVI is increased due
to age of the patients and the presence of numerous
concomitant diseases. Bleeding complications and
blood transfusions worsen the early and long-term
prognosis of patients after interventions [3–6].
The aim of the study was to assess the risk of
bleeding complications and their influence on early
prognosis of patients undergoing TAVI. Additional
aim was to analyze the utility of the TIMI [7] and
GUSTO [8] bleeding scales in the evaluation of
bleeding complications and the usefulness of those
scales in prediction of blood transfusion necessity
in the early post-procedural period.
Methods
The study included 56 consecutive patients
between 62 and 91 years of age (81.89 ± 6.12) who
underwent TAVI in the Institute of Cardiology in
Warsaw between January 2009 and February 2011.
This was a single center, observational study
of early, in-hospital bleeding complications related
to TAVI, retrospective until February 2011 and
from that point on prospective. Analyzed parame-
ters were: (1) risk factors of bleeding complications
in the HASBLED scale: hypertension, renal failure,
liver failure, previous stroke/transient ischemic
attack (TIA), previous bleeding, history of anemia,
nontherapeutic international normalized ratio
(INR), age, use of antiplatelet drugs or nonsteriodal
anti-inflamatory drugs, alcohol abuse, (2) diabetes
mellitus type 2, (3) female sex, (4) the route of bio-
prosthesis implantation — transarterial or transapi-
cal and (5) pre- and post-procedural antithrombotic
treatment. Although in 2011 Valve Academic Re-
search Consotrium (VARC) had already created
a scale dedicated for TAVI bleedings [9], we used
two known bleeding scales: TIMI [7] and GUSTO
[8] for bleeding classification. We decided to com-
pare their utility in bleedings classification and pre-
dictory value in the assessment of blood transfusion
necessity. Major bleeding according to TIMI scale
was defined as intracranial hemorrhage or a ≥ 5 g/dL
decrease in the hemoglobin concentration (HGBc) or
a ≥ 15% absolute decrease in the hematocrit (HCT).
Minor bleeding according to TIMI scale was defined
as observed blood loss with ≥ 3 g/dL decrease in the
HGBc or ≥ 10% decrease in the HCT, or non ob-
served blood loss with ≥ 4 g/dL decrease in the HGBc
or ≥ 12% decrease in the HCT. Minimal TIMI bleed-
ing was defined as any clinically overt sign of hemor-
rhage (including imaging) that is associated with
a < 3 g/dL decrease in the HGBc or < 9% decrease in
the HCT. Severe or life-threatening bleeding accor-
ding to GUSTO scale was defined as either intracra-
nial hemorrhage or bleeding that causes hemodynamic
compromise and requires intervention. Moderate
bleeding according to GUSTO scale was deifined as
bleeding that requires blood transfusion but does not
result in hemodynamic compromise. Mild GUSTO
bleeding was defined as bleeding that does not meet
criteria for either severe or moderate bleeding.
The history of anemia was defined as HGBc
< 12 g/dL, diagnosed on the basis of blood count
a day before the procedure. The decrease in HGBc
and HCT after TAVI was assessed on the basis of
blood count, collected every day during 2 consecu-
tive days and fiveth day after the procedure, which
was compared with HGBc and HCT value on a day
before the procedure. The transfusion was made
when the post-TAVI HGBc was £ 10.0 g/dL, HCT
£ 30.5% and decrease in HGBc was ≥ 1.5 g/dL, in
HCT ≥ 5%, or when the post-procedural HGBc was
£ 9.5 g/dL, or HCT £ 28% and patient had peri-
procedural vascular complications which could pos-
sibly lead to further decline in HGBc or HCT. The
decision of the the number of transfused pocket red
blood cells units (PRBCu) was based on the indi-
vidual physiscian evaluation.
Vascular complications were defined as injury
of the vessels (femoral artery, iliac artery, aorta)
directly related with the bioprosthesis implantation,
access site or acess access-related vascular injury
(dissection, stenosis, perforation, rupture, arterio-
venous fistula, pseudoaneurysm, haematoma), also
pleural hemathoma or haemorhage during transapi-
cal aortic-valve implantation (TA-AVI), which can
lead to death, need for blood transfusions and/or
unplanned percutaneous or surgical intervention or
requiring compression or thrombin injection ther-
apy in the case of pseudoaneurysm.
All patients undergoing the procedure had at
least mild bleeding and due to the small number of
the paricipants, in all statistical analyzes the mode-
rate/minor and severe/major TIMI/GUSTO bleedings
were assessed together as serious bleedings vs.
mild/minimal incidents. The studied group was di-
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vided into two subgroups to assess the influence of
a learning curve on cardiovascular complications.
Severe aortic valve stenosis was defined ac-
cording to the European Society of Cardiology
(ESC) criteria on the diagnosis and management of
valve diseases published in 2007 [1]. Patients were
qualified for the TAVI procedure according to ESC/
/European Association of Cardio-Thoracic Surgeons
(EACTS) criteria prepared in collaboration with
European Association on Percutaneous Coronary
Interventions (EAPCI) in 2008 [2]. Two types of
protheses were used: Edwards-Sapien or Sapien XT
(ES) bioprosthesis (Edwards Lifesciences) of 23 and
26 mm diameter with 18 and 22-French vascular
sheath systems and CoreValve (CV) bioprosthesis
(CoreValve Revalving System, Medtronic) of 26 and
29 mm diameter with the system of 18 French de-
livery cetheters. The type of bioprosthesis and the
route of implantation were adjusted to the size of the
native valve annulus and to the diameter and status
of peripheral arteries. The TAVI procedure was per-
formed under aseptic conditions in catheterization
laboratory under general anesthesia and guided with
transesophageal echocardiography. For the CV pros-
thesis a transfemoral or transsubclavian access were
used and for the ES prosthesis a transfemoral or tran-
sapical access were applied depending on the ana-
tomic conditions. All patients received unfractionat-
ed heparin during the procedure under activated
partial thromboplastin time control.
The study was approved by the local research
ethics committee and all patients in prospective
part of the study were asked for written informed
consent.
Statistical analysis
Univariate and multivariate statistical analysis
was performed with means of the SAS system. Cate-
gorical data are presented as frequencies and per-
centages; continuous variables are expressed as
means ± SD. Comparisons were made with the
c2 statistic test or, when appropriate, the Fisher ex-
act test for categorical variables and with the non-
parametric Wilcoxon signed rank test for continu-
ous variables. Uni- and multivariate logistic regres-
sion model with stepwise method selection of
significance with odds ratios (ORs) and 95% confi-
dence interval (CI) was performed to identify inde-
pendent variables predicting the risk of in-hospital
serious bleedings. Because of the small number of
participants on various drugs combinations we did
not perform multivariate analysis of peri-procedural
treatment. For all statistical tests, a significance
level of p < 0.05 was used.
Results
The analysis included a group of 56 consecu-
tive patients with severe, symptomatic aortic valve
stenosis disqualified from surgical aortic valve re-
placemnet due to high procedural risk and/or lack
of technical possibilities to perform the procedure.
Detailed characteristics of patients undergoing
TAVI is presented in Table 1.
Bleeding in the early post-procedural period
occurred in all patients who underwent TAVI. Mode-
rate and severe bleeding complications were noted
in 35 (62.5%) patients: 29 (51.78%) patients fulfilled
Table 1. Baseline characteristics of the 56 patients.
Age [year] 81.89 ± 6.13
Female sex 36 (64.28%)
Logistic EuroSCORE [%] 6.59–59.1
(27.69 ± 13.00)
Implantation:
TF-AVI/TSC-AVI 38/4 (67.85%/7.14%)
TA-AVI 14 (25%)
NYHA class:
II 3 (5.35%)
III 39 (69.64%)
IV 14 (25%)
Coronary artery disease 45 (80.35%)
Previous myocardial infarction 15 (26.78%)
Previous intervention:
PCI 21 (37.5%)
CABG 9 (16.07%)
COPD 20 (35.71%)
Atrial fibrillation 23 (41.07%)
Permanent pacemaker: 12/25
pre/post TAVI (21.42%/44.64%)
Pulmonary hypertension 37 (66.07%)
Extensively calcified aorta 3 (5.35%)
Osteoporosis 16 (28.57%)
BMI [kg/m2] 25.32 ± 3.21
Echocardiographic data:
AVA [cm2] 0.65 ± 0.11
Aortic PG max [mm Hg] 100 ± 22.71
Aortic PG med (mm Hg] 60.78 ± 17.09
LVEF [%] 51.94 ± 13.65
   Ejection fraction < 50% 24 (42.10%)
TF-AVI — transfemoral aortic valve implantation; TSC-AVI — trans-
subclavian aortic valve implantation; TA-AVI — transapical aortic
valve implantation; NYHA — New York Heart Association class of
heart failure; PCI — precutaneous coronary intervention; CABG —
coronary-artery bypass grafting; COPD — chronic obstructive pul-
monary disease; BMI — body mass index; AVA — aortic valve area;
PG — pressure gradient; LVEF — left ventricular ejection fraction
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the GUSTO scale criteria and 19 (33.92%) patients
met the TIMI scale criteria; 33 of the 35 severe
bleeding complications (94.28%) were related to the
route of bioprosthesis implantation. There were
17 vascular complications among 28 patients who
underwent TAVI earlier in the study in comparison
to 16 complications among 28 patients who under-
went the procedure later in the study. Learning
curve did not influence vascular complications
related to serious bleeding (p = NS). The frequen-
cy of bleeding according to the GUSTO and TIMI
scales and the number of transfused PRBCu are pre-
sented in Table 2. The peri-procedural HGBc and
HCT value are presented in Table 3. The type of
bleeding complications in the early post-procedur-
al phase and their influence on in-hospital mortali-
ty is summarized in Table 4.
The prevalence of analyzed risk factors in
56 patients and their relation to bleeding defined by the
GUSTO and TIMI scales are presented in Table 5.
Univariate analysis demonstrated that the only
predictor of serious bleeding complications accord-
ing to the GUSTO and TIMI scales is the history of
anemia (p = 0.0013 and p = 0.048, respectively).
Univariate logistic regression analysis showed that
history of anemia is predictor of serious bleeding
only according to GUSTO scale.
The influence of pre-procedural pharmacothera-
py on bleeding after TAVI was analyzed. 52 (92.85%)
patients were on antithrombotic treatment before
TAVI. No bleeding complications after intervention
were observed in patients on vitamin K antagonist
(VKA) monotherapy prepared for the procedure as
recommended. All other patients suffered from
bleeding complications. The risk of bleeding accord-
ing to the GUSTO or TIMI scales in every subgroup
in relation to VKA was compared (Table 6).
Subsequently the analysis focused on the in-
fluence of antithrombotic treatment after TAVI on
Table 2. Bleeding according to the GUSTO and TIMI scales and blood transfusion after TAVI in 56 patients.
GUSTO TIMIBleeding
Bleeding Transfusion PRBCu Bleeding Transfusion PRBCu
classifications
no./%  pts. no. min.–max. no./% pts. no. min.–max.
(PRBCu/pt) (PRBCu/pt)
Mild/minimal 26/46.42% 2 (3) 0–2 (0.05 ± 0.29) 37/66.07% 17 (44) 0–5 (0.78 ± 1.37)
Moderate/minor 21/37.5% 21 (2.28) 1–4 (0.85 ± 1.27) 14/25.0% 11 (3.09) 0–16 (0.64 ± 2.25)
Severe/major 8/14.28% 8 (7.0) 1–17 (1.07 ± 3.38) 5/8.92% 3 (9.66) 0–17 (0.55 ± 2.60)
Serious* 29/51.78% 29 (3.58) 1–17 (1.92 ± 3.35) 19/33.92% 14 (4.5) 0–17 (1.19 ± 3.33)
*(p = 0.03): incidents of blood transfusions in serious GUSTO bleedings vs. serious TIMI bleedings; pts. no. — patients number; PRBCu — pocket red
blood cells units; PRBCu/pt — pocket red blood cells units per patient
early bleeding complications. One patient who died
after few hours after the procedure due to disrup-
tion of the arotic wall and left ventricle during pros-
thesis implantation was excluded from the treat-
ment analysis. Three patients were maintained on
clopidogrel monotherapy due to high risk of bleeding
complications. All other patients received a combined
therapy. Bleeding was not observed only in patients
treated after TAVI with VKA and clopidogrel. Safety
of treatment with VKA plus clopidogrel in comparsion
to other drugs used is presented in Table 7.
There is no scale to assess the risk of bleeding
complications among patients undergoing TAVI.
The HASBLED scale constructed for patients with
atrial fibrillation (AF) chronically treated with anti-
thrombotic drugs was used for the purpose of the
presented analysis. Almost all patients in the stud-
ied group (52 patients, 92.85%) had a high risk of
bleeding in the HASBLED scale (≥ 3 points). Low
risk was observed in only 4 patients of whom 3 suf-
fered from bleeding complications defined as ma-
jor in the TIMI scale and 2 had bleeding complica-
tions defined as severe in the GUSTO scale. There
was no significant correlation between the HAS-
BLED score and the number of patients with seri-
ous bleeding according to the TIMI and GUSTO
scale (p = 0.07 and p = 0.88, resepectively). Blood
transfusion was necessary in all patients 29 (100%)
patients with serious GUSTO bleeding. They received
a total number of 104 PRBCu and 3.58 PRBCu per
patient. Analogically, blood transfusion was neces-
sary in 14 of the 19 (73.98%) patients with serious
TIMI bleeding; a total number of 63 PRBCu was
transfused, 4.5 PRBCu per patient (Table 2). Pa-
tients with serious GUSTO bleeding required blood
transfusion more frequently than patients with se-
rious TIMI bleeding (p = 0.03).
There were 4 deaths during hospitalization.
Three of them were caused by bleeding complications:
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2 related to the vascular complications and 1 caused
by massive bleeding from the upper gastrointesti-
nal tract. A fourth death which occurred in the dis-
tant day of hospitalization was caused by decompen-
sated heart failure. Serious bleeding did not have
impact on in-hospital mortality (p = 0.29), irrespec-
tive of the GUSTO and TIMI classification (p = 0.37
and p = 0.07, respectively), similarly as incidents od
blood transfusions (p = 0.41) and PRBCu (p = 0.28).
None of analized factors for TIMI bleeding en-
tered into the multivariate model, because of its
insignificance in univariate regression analysis. In
stepwise regression analysis of GUSTO risk factors
only anemia was significant predictor of in-hospital
serious bleeding (OR 6.750; 95% CI 1.946–23.416;
p = 0.0026).
Discussion
Presented population is typical for TAVI. Mean
logistic Euroscore value was 27.69 ± 13.00%. Few
patients were qualified for TAVI despite low Euro-
score values due to the presence of risk factors not
included in the prognostic scales such as porcelain
aorta or diffused osteoporosis. Low Euroscore or
STS values in these patients demonstrate that those
scales are suboptimal and for that reason construc-
tion of new scales has been proposed [10, 11]. Most
frequently described early, in-hospital complica-
tions of TAVI include: vascular complications,
bleeding, stroke and TIA, death, the need of pace-
maker implantation and acute renal failure [12–18].
In our study serious bleeding complications were
observed in 35 (62.5%) patients. Almost all of the
early bleeding complications 33 (94.3%) were re-
Table 4. The causation of moderate and severe
bleeding complications in early post-procedural
phase and their influence on in-hospital mortality.
In hospital bleeding No. (%) Death no.
after TAVI
Vascular complications:
TF-AVI/TSC-AVI 24 (42.85%) 2
TA-AVI (pleural 9 (16.07%) 0
haemorrhage)
Gastrointerstinal 1 (1.78%) 1
haemorrhage
Pericardial tamponade 1 (1.78%) 0
Without bleeding 21 (37.5%) 1
Total 56 (100%) 4 (7.14%)
TF-AVI — transfemoral aortic valve implantation; TSC-AVI — trans-
subclavian aortic valve implantation; TA-AVI — transapical aortic
valve implantation
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lated to the vascular complications. The number of
vascular complications in the first and second year
since the introduction of the procedure in our cen-
ter was not significantly different and therefore was
not related to the learning curve. The high propor-
tion of reported serious bleeding and vascular com-
plication is a result of a cumulative assessment of
severe and moderate bleedings due to small partic-
ipants number. In fact, major bleedings occurred
between 8–15% of patients according to the used
bleeding scales. Moreover vascular complications
were not divided according to their severity. Simi-
larly to our analysis, other authors report that ear-
ly, major bleeding complications after TAVI affect
between 9% and 31% of patients [12–17]. In a single
center analysis Nuis et al. [12] proved that severe
bleeding occured in 31% of patients and was the
most frequent complication in the early post-proce-
dural period. In the PARTNER study early, serious
bleedings were registered in 9% to 16% of patients
Table 5. The prevalence and predictive value of bleeding risk factors on serious bleeding according to
the GUSTO and TIMI scales in c2 and univariate logistic regression analysis in 56 patients.
Variables GUSTO bleeding P OR (95%CI); p
Yes (n = 29)/No (n = 27)
Hypertension 21 (72.41%)/13 (48.14%) 0.3 0.457 (0.120–1.740); 0,25
Abnormal renal function* 17 (58.62%)/15(55.55%) 0.64 1.133 (0.393–3.269); 0.81
Abnormal liver function† 1 (3.44%)/2 (7,4%) 0.47 0.446 (0.038–5.227); 0.52
History of stroke/TIA 2 (6.89%)/4 (14.81%) 0.29 0.326 (0.058–1.845); 0.20
History of bleeding 2 (6.89%)/4 (14.81%) 0.29 0.426 (0.071–2.541); 0.34
Anemia‡ 21 (72.41%)/7 (25,92%) 0.0013 7.500 (2.293–24.527); 0.0009
Labile INRs 0 (0%)/2 (7.4%) 0.12** ***
Age [year] 83.35 ± 5.88/80.33 ± 6.11 0.16 1.092 (0.991–1.204); 0.07
Drugs (antiplatelet agents/ 2 (6.89%) 0 (0%) 0.49** ***
/NSAIDs)§/Alkohol abuse
Diabetes mellitus 10 (34.48%)/14 (51.85%) 0.31 0.489 (0.167–1.432); 0.19
Female sex 20 (68.96%)/16 (59.25%) 0.45 1.528 (0.509–4.586); 0.44
Implantation:
   TF-AVI+TSC-AVI 19 (65.51%)/23 (85.18%) 0.3  3.026 (0.817–11.206); 0.09
   TA-AVI 10 (34.48%)/4 (14.81%)
Variables TIMI bleeding P OR (95%CI); p
Yes (n = 19)/No (n = 37)
Hypertension 13 (68.42%)/21 (56.75%) 0.18 0.419 (0.114 - 1.545); 0.19
Abnormal renal function* 10 (52.63%)/22 (59.45%) 0.62 0.758 (0.249-2.309); 0.62
Abnormal liver function† 1 (5.26%)/2 (5.40%) 0.96 0.972 (0.083-11.459); 0.98
History of stroke/TIA 3 (15.78%)/3 (8.1%) 0.37 1.547(0.309-7.752); 0.59
History of bleeding 1 (5.26%)/5 (13.51%) 0.34 0.356 (0.038-3.285); 0.36
Anemia‡ 6 (31.57%)/22(59.45%) 0.048 0.315 (0.098-1.013); 0.52
Labile INRs 0 (0%)/2 (5.40%) 0.54** ***
Age [year] 82.32 ± 4.99/81.68 ± 6.69 0.62 1.018 (0.927–1.117); 0.70
Drugs (antiplatelet agents/ 2 (10.52%)/0 (0%) 0.11** ***
NSAIDs)§/Alkohol abuse
Diabetes mellitus 10 (52.63%)/14 (37.83%) 0.56 1.825 (0.596–5.589); 0.29
Female sex 12 (73.68%)/24 (64.86%) 0.87 0.929 (0.294–2.935); 0.89
Implantation:
   TF-AVI+TSC-AVI 15 (78.94%)/27 (72.97%) 0.25  0.720 (0.192–2.696); 0.62
   TA-AVI   4 (21.05%)/10 (27.02%)
*Serum creatinine ≥ 200 µmol/L or GFR < 60 mL/min/1.73 m2; †Chronic hepatic disease or bilirubin > 2 × upper limit of normal, in association with
aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase > 3 × upper limit normal; ‡History of anemia and/or Hgb < 12.0 g/dL on
day before the procedure; §Drugs: described separately; **According to Fisher exact test; ***Because of a small numer of patients results are not reliable;
TIA — transient ischemic attack; INR — international normalized ratio; TF-AVI — transfemoral aortic valve implantation; TSC-AVI — transsubclavian
aortic valve implantation; TA-AVI — transapical aortic-valve implantation; NSAIDs — nonsteroid antiinflamatory drugs
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referred for the procedure. A high proportion of
bleeding was also observed at 1 year after the pro-
cedure (14.7–22.3%) [16, 17]. In a meta-analysis of
12 studies analyzing prognostic influence of bleed-
ing after TAVI Moreno et al. [15] demonstrated that
early bleeding and vascular complications are re-
sponsible for almost 18% of deaths in the first
30 days after the procedure. In the study on 150 pa-
tients Nuis et al. [12] noted that 16% of early vas-
cular complications were strongly related to bleed-
ing events. Results of SOURCE registry demon-
strated that vascular complications are observed in
22.9% of patients significantly increasing short-
term mortality after transapical implantation [13].
Early vascular complications affect up to 34% of
patients undergoing the procedure and lead to 2- to
3-fold increase of the risk of 30-day mortality after
TAVI [12, 18]. The most probable cause is antiplate-
let and antithrombotic treatment used before the
procedure as well as treatment started after the pro-
cedure. Moreover, advanced age and comorbidities
present in this population put it at high risk of fre-
quent bleeding complications. No study analyzing
the relation between anticoagulation and bleeding
after TAVI has been published so far. This is par-
ticularly important as the scheme of DAPT was
proposed as a standard of treatment before condu-
cion of studies on this population of patients [2].
Most of the reports regarding the risk of combined
therapy with DAPT comes from the studies on pa-
tients with acute coronary syndrome [3, 19–22]. It
is known that bleeding complications are observed
in 2–8% of patients with coronary artery disease and
are more frequent in women, in elderly, in patients
with renal dysfunction and those with a history of
bleeding [3–5]. Many studies confirmed that the use
of DAPT with oral anticoagulants efficiently reduc-
es the risk of recurrent coronary incidents, but is
related to worse prognosis due to increased risk of
bleeding [19–22]. Chronic use of triple anticoagu-
lant therapy (TAT) in population of patients > 75 ye-
ars of age is related to 15% risk of bleeding compli-
cations per each year of treatment [22]. In a retro-
spective analysis Karjalainen et al. [19] found that
TAT is related to higher frequency of bleeding
complications (11.4%) and worse 1-year prognosis.
Similarly Manzano-Fernández et al. [21] confirmed
that TAT is an independent risk factor of bleeding
in long-term observation. On the contrary, a large
GRACE registry demonstrated that TAT is related
to only 6% of severe bleding in the early post-pro-
cedural period [20]. Reports on the surgical proce-
dure in patients on DAPT also demonstrate that
bleeding occurs in several percent of patients [23–
–25]. Therefore according to EACTS recommenda-
tions antiplatelet treatment with clopidogrel should
be interrupted at least 5 days before the procedure
depending on the risk of bleeding and thrombo-
embolic incidents [23, 24]. Our study demonstrat-
ed that the safest therapy consists of VKA before
the procedure and a combined therapy with VKA
and clopidogrel after TAVI. VKA is recommended
after surgical valve replacement (SVR) [1, 26]. This
type of treatment is related to bleeding complica-
tions of 1 to over 5%/year depending on the type of
the prosthesis and the clinical characteristics of
patients [26]. It is proved that the maintenance of
therapeutic INR values reduces the number of
Table 6. The univariate analysis of impact of
antithrombotic therapy pre-TAVI on serious
bleeding according to the TIMI and GUSTO scale,
in comparison with VKA monotherapy (n = 5).
Antithrombotic therapy pre-TAVI
(GUSTO bleeding no./pts. no.) (n = 52)*
ASA (n = 14/27) p = 0.026
Clopidogrel + ASA (n = 8/11) p = 0.007
Clopidogrel + ASA + VKA (n = 3/5) p = 0.038
VKA + ASA (n = 4/9) p = 0.07
Antithrombotic therapy pre-TAVI
(TIMI bleeding no./pts. no.) (n = 52)*
ASA (n = 9/27) p = 0.11
Clopidogrel + ASA (n = 6/11) p = 0.044
Clopidogrel + ASA + VKA (n = 2/5) p = 0.11
VKA + ASA (n = 3/9) p = 0.14
*Four patients without antithrombotic therapy; VKA — vitamin K
antagonists; ASA — acetylsalicylic acid
Table 7. Bleeding complications dependent on
antithrombotic therapy after TAVI in comparison
with VKA + clopidogrel (n = 4).
Antithrombotic therapy post-TAVI
(GUSTO bleeding no./pts. no.) (n = 51)*
Clopidogrel (n = 2/3)** p = 0.053
Clopidogrel + ASA (n = 17/29) p = 0.04
Clopidogrel + ASA + VKA (n = 6/8) p = 0.014
VKA + ASA (n = 3/11) p = 0.24
Antithrombotic therapy post-TAVI
(TIMI bleeding no./pts. no.) (n = 51)*
Clopidogrel (n = 1/3)** p = 0.21
Clopidogrel + ASA (n = 11/29) p = 0.13
Clopidogrel + ASA + VKA (n = 1/8) p = 0.46
VKA + ASA (n = 5/11) p = 0.09
*One early death due to disruption of aorta;**high risk of bleeding;
VKA — vitamin K antagonists; ASA — acetylsalicylic acid
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bleeding complications [23, 27]. In a retrospective
analysis Karjalainen et al. [19] suggested that the
safest therapy in patients undergoing percutaneous
coronary interventions (PCI) with high risk of
bleeding consists of the combination of VKA and
clopidgrel. Monotherapy with VKA after 1 year of
combined treatment is also considered as the saf-
est one in patients with AF after PCI [21, 22]. We
have no experience with VKA monotherapy after
the procedure because the standard of antithrom-
botic treatment after TAVI consists of antiplatelet
drugs with VKA added in patients with AF. Our
results underline the value of monitored VKA
monotherapy before and with clopidogrel after the
procedure. Therefore we believe that VKA mono-
therapy should be considered as standard of care
after TAVI with clopidogrel added only in patients
after stent implantation in the preceeding
12 months. Studies on larger populations of patients
undergoing TAVI are needed. To search for other
causes of severe bleeding complications after TAVI
established risk factors of bleeding complications
were analyzed [3, 28–32]. As there is no specific
scale to assess the risk of bleeding complications
in the population of patients undergoing TAVI the
HASBLED scale has been chosen [28]. All elements
of the HASBLED scale were included in the analy-
sis. The scale is dedicated to assess the risk of
bleeding complications in patients with AF. TAVI
population is a high risk population with almost all
patients scoring 1 point for age over 65 years and
with the presence of many comorbidities. There-
fore, it was impossible to confirm the relation be-
tween high risk of bleeding in the HASBLED scale
and the occurrence of severe bleeding complica-
tions. Univariate analysis of risk factors included in
the HASBLED scale showed that the history of
anemia and/or HGBc < 12.0 g/dL determined dur-
ing 24 hours preceeding TAVI were the strongest
independent predictors of bleeding. None of the oth-
er established risk factors increased the frequency
of severe bleeding complications after TAVI. This
is concurent with the results of many studies which
confirmed that anemia significantly increases the
risk of bleeding complications and is an independent
risk factor of early and long-term mortality in pa-
tients undergoing PCI or SVR [3, 28–32]. Cladellas
et al. [30] demonstrated that HGBc < 12.0 g/dL be-
fore SVR is an independent risk factor of in-hospi-
tal mortality. Anemia is also a prognostic factor in
heart failure [3, 31]. Our resluts are consistent with
the latest reports form Halliday et al. [33] and van
Mieghem et al. [34], authors discovered that near-
ly 50% of patiens had anemia before TAVI, which
was an independent predictor of in-hospital serious
bleedings after the procedure and long-term mor-
tality. Although 50% of patients in our analysis had
anemia diagnosed on a day before TAVI we had not
menaged to investigate properly the causation of it,
mainly because of observational and retrospective
character of our study. Possible reasons are ad-
vanced age of TAVI patients and coexistence of
chronic renal impariment, which afected almost
60% of analyzed population. On the other hand,
more than 90% of our patients had chronic use of
many types of antithrombotic therapy before the
procedure which could lead to no overt bleeding in
past. The occurrence of Heyde syndrome in patients
with aortic stenosis is also commonly known. Ad-
ditional aim of the study was to validate the utility
and prognostic value of bleeding scales in the clas-
sification of bleedings after TAVI. Although VARC
had already created scale for bleeding classification
after TAVI [9], we decided to use two known scales
(TIMI and GUSTO) mainly due to their different
criteria for bleedings classification [35, 36]. The
TIMI scale is based on laboratory changes and
GUSTO scale is based on clinical outcomes and
blood transfusions. The need of blood transfusion
which is an independent, negative predictive fac-
tor was also analyzed [6]. Moderate and severe
GUSTO bleeding events occurred in over 50% of
patients and major and minor TIMI bleedings were
found in over 30% of patients. The effort to com-
pare the prognostic value of both scales has been
made. Moderate and severe the GUSTO bleeding
was related to more frequent incidents of blood
transfusion in comparison to the TIMI bleeding.
This finding is concurent with the observations of
Rao et al. [35] who based on the meta-analysis sug-
gested superiority of GUSTO scale over TIMI scale
in terms of sensitivity, specificity and predicitive
value of bleeding. The VARC bleeding scale seems
to be a combination of these two abovementioned
[9] and in our further analysis, on a larger group of
participants we will evaluate its prognostic value.
Although it was proved that early, post-TAVI
bleeding and blood transfusions increased in-hos-
pital mortality [9, 13, 15, 33, 34], we could not con-
firm this findings in our analysis. The main limita-
tion of our study was small number of participants
and observational character of partially retrospec-
tive analysis, but further studies of pre-procedural
anemia and impact on antithrombotic therapy on
bleeding complications on a larger patients number
is extremely required.
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Conclusions
1. History of anemia is the strongest predictor of
serious bleeding in the GUSTO scale.
2. Oral anticoagulants used in monotherapy be-
fore TAVI and in combination with clopidogrel
after the procedure are safer than antiplatelet
therapy and triple drug treatment.
3. The TIMI and GUSTO scales can adequately
classify bleeding after TAVI however the GUSTO
scale is a better predictor of blood transfusion.
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